|
Código del ensayo CLL18 / MOIRAI |
|
Ensayo A phase 3 multicenter, randomized, prospective, open-label trial of fixed-duration (12 months) venetoclax/obinutuzumab vs. Fixed-duration (15 months) venetoclax/pirtobrutinib vs. Mrd-guided venetoclax/pirtobrutinib in patients with previously untreated chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll) aiming to establish measurement of individual residual disease for adaption of treatment duration to improve outcome. (moirai) |
|
Estado Abierto a inclusión |
|
Localización Tumoral Hematológicos |
|
Tipo de tumor Leucemia linfática crónica |
|
Tipo de ensayo Ensayo de Fase III |
|
Tipo de tratamiento |
|
Situación clínica |
|
Centro |
